Supplementary Table S2. Pancreatic cancer patient characteristics by lorazepam prescription records.

		No	Yes	P-value
Overall	N	141 (39.5)	216 (60.5)	
Age @ Dx	Mean/Std/N	65.3/9.8/141	62.7/11.0/216	0.060
	Median/Min/Max	65.1/36.2/91.6	63.1/24.1/84.6	
Age @ Chemo	Mean/Std/N	65.4/9.7/141	62.9/11.0/216	0.061
	Median/Min/Max	65.1/39.3/91.6	63.2/24.1/84.7	
Sex	Male	76 (53.9%)	97 (44.9%)	0.105
	Female	65 (46.1%)	119 (55.1%)	
Race	White	125 (90.6%)	205 (96.7%)	0.037
	Black	10 (7.2%)	4 (1.9%)	
	Other	3 (2.2%)	3 (1.4%)	
Alcohol	Never	39 (29.8%)	72 (35.1%)	0.005
	Former	21 (16.0%)	11 (5.4%)	
	Current	71 (54.2%)	122 (59.5%)	
Tobacco	Never	49 (35.5%)	84 (39.3%)	0.652
	Former	54 (39.1%)	84 (39.3%)	
	Current	35 (25.4%)	46 (21.5%)	
Grade	I		2 (3.6%)	0.618
	II	18 (43.9%)	21 (37.5%)	
	III	20 (48.8%)	28 (50.0%)	
	IV	3 (7.3%)	5 (8.9%)	
Clinical Stage	I	24 (18.2%)	35 (17.7%)	0.999
	II	21 (15.9%)	31 (15.7%)	
	III	25 (18.9%)	38 (19.2%)	
	IV	62 (47.0%)	94 (47.5%)	
Path Stage	0	1 (1.9%)	1 (1.3%)	0.756
	I	2 (3.8%)	2 (2.6%)	
	II	29 (55.8%)	36 (47.4%)	
	III		1 (1.3%)	
	IV	20 (38.5%)	36 (47.4%)	
Nodes Examined	Mean/Std/N	5.5/11.5/140	4.4/9.6/212	0.210
	Median/Min/Max	0.0/0.0/71.0	0.0/0.0/47.0	
Nodes Positive	Mean/Std/N	1.9/2.4/40	2.6/2.8/47	0.208
	Median/Min/Max	1.0/0.0/10.0	2.0/0.0/12.0	
Nodes	Negative	14 (35.0%)	13 (27.7%)	0.493
	Positive	26 (65.0%)	34 (72.3%)	
Persistent Disease	No	29 (20.6%)	40 (18.5%)	0.681
	Yes	112 (79.4%)	176 (81.5%)	
Tx: XRT	No	117 (83.0%)	173 (80.1%)	0.580
	Yes	24 (17.0%)	43 (19.9%)	
Tx: Immuno	No	136 (96.5%)	207 (95.8%)	1.000
	Yes	5 (3.5%)	9 (4.2%)	
Tx: Hormone	No	137 (97.2%)	211 (97.7%)	0.744
	Yes	4 (2.8%)	5 (2.3%)	
Tx: Surgery	No	11 (7.8%)	20 (9.3%)	0.703
	Yes	130 (92.2%)	196 (90.7%)	
Timing of BZD	Prior to Start of Chemo	79 (56.0%)	78 (36.1%)	<.001
	After Start of Chemo	59 (41.8%)	138 (63.9%)	
	At Start of Chemo	3 (2.1%)		

Tx:Surgery refers to all surgical procedures including biopsies and partial resections